Iris Parent Holding Corp.

Iris Parent Holding Corp. is a holding company formed to facilitate the business combination between Iris Acquisition Corp. and Liminatus Pharma, Inc. Its primary purpose is to serve as the parent entity for Liminatus Pharma, a clinical-stage biopharmaceutical company focused on the development of targeted therapies for cancer and rare diseases. This transition to a public company structure was completed through a merger, finalized in April 2025, with Iris Parent Holding Corp. assuming the publicly traded identity for the combined enterprise. The company plays a key role in the pharmaceutical and biotechnology sector, supporting innovative drug discovery and development initiatives. As a result of the merger, Iris Parent Holding Corp. now holds significant interest in Liminatus Pharma’s pipeline and operations, extending its reach in the healthcare industry. Through this structure, the entity provides both strategic oversight and access to public market capital, thereby enabling Liminatus Pharma to advance its research programs and commercial objectives. The asset is particularly significant for investors seeking exposure to cutting-edge developments in biotechnology through a company with an established public market presence.